[The role of the enzymatic antioxidant system and Helicobacter pylori infection in the pathogenesis of peptic ulcer and their effect on treatment efficacy].
OBJECTIVE
To assess activity of superoxide dismutase and catalase in acute ulcer and in the end of its treatment with antisecretory (omeprasole and zaran), anti-Helicobacter (metronidasole) and antioxidant (alpha-tocopherol) drugs in patients with duodenal ulcer.


METHODS
126 patients with duodenal ulcer were divided into 6 groups: group 1 patients had Helicobacter pylori (HP+) and were given omeprasole; group 2 patients had HP and were given omeprasole + metronizarole; group 3 patients were free of HP and received metronidasole + alpha-tocopherol; group 4 HP+ patients received zaran; group 5 HP+ patients got zaran = metronidasole; group 6 free of HP received zaran + alpha-tocopherol. The patients were examined using esophagogastroduodenoscopy, roentgenoscopy of the stomach, tests of the gastric juice.


RESULTS
An acute phase of ulcer was accompanied with enhanced activity of superoxide dismutase and low activity of catalase in mucosal biopsies from ulcer lesion and periulcer zone. In remission, antioxidant system resumed normal activity depending on the kind of the combined therapy. The combination omeprasole + metronidasole was more effective in HP eradication than zaran + metronidasole. Effect of alpha-tocopherol was poor.


CONCLUSIONS
It is suggested that HP stimulates lipid peroxidation and thus maintains inflammation in gastric and duodenal mucosa.
Esedov
E M
EM
Muradova
V R
VR
Mamaev
S N
SN
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism*; D001706:Biopsy; D002374:Catalase / Q000378:metabolism*; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D005260:Female; D005753:Gastric Mucosa / Q000201:enzymology* / Q000473:pathology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D013276:Stomach Ulcer / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D013482:Superoxide Dismutase / Q000378:metabolism*
D000897:Anti-Ulcer Agents; D000975:Antioxidants; D002374:Catalase; D013482:Superoxide Dismutase